Skip to content

Research on the mechanism of ALAN exposure on early puberty development and its interference with kisspeptin

Research on the mechanism of ALAN exposure on early puberty development and its interference with kisspeptin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113754
Enrollment
Unknown
Registered
2025-12-02
Start date
2025-04-22
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Puberty Development

Interventions

High exposure group to ALAN:NA
Low exposure group to ALAN:NA

Sponsors

Peking University Health Science Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 10 Years

Inclusion criteria

Inclusion criteria: 1. 8-10 years old at baseline survey 2. The development of secondary sexual characteristics has not yet entered the second stage of Tanner 3. The child and guardian agree to sign the informed consent for the follow-up investigation 4. There is no transfer plan within 2 years

Exclusion criteria

Exclusion criteria: 1. Tanner Phase II has been entered at the time of baseline investigation 2. Those with abnormal physical development (such as dwarfism, gigantism, etc.) 3. Those with physical disability and deformity, such as severe scoliosis, chicken breast, lameness, etc 4. Those with major organ diseases (such as heart disease, liver disease, kidney disease, etc.) 5. Those with endocrine diseases, such as diabetes, hyperthyroidism or insufficiency, other endocrine diseases, etc 6. Those who do not agree to participate in the secondary sex screening and follow-up survey

Design outcomes

Primary

MeasureTime frame
Breast development level;E2;TT;FSH;LH;

Secondary

MeasureTime frame
BMI;kisspeptin;

Countries

China

Contacts

Public ContactYi Song

Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing, China

songyi@bjmu.edu.cn+86 135 0138 7295

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026